World Library  
Flag as Inappropriate
Email this Article

Way-100,635

Article Id: WHEBN0016019404
Reproduction Date:

Title: Way-100,635  
Author: World Heritage Encyclopedia
Language: English
Subject: WAY-100,135, 5-HT1A receptor, Flibanserin, Mepiprazole, Tiospirone
Collection: Amides, Dopamine Agonists, Phenol Ethers, Piperazines, Pyridines, Serotonin Antagonists
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Way-100,635

WAY-100,635
Systematic (IUPAC) name
N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- N-(2-pyridyl)cyclohexanecarboxamide
Identifiers
CAS Registry Number  YesY
PubChem CID:
IUPHAR/BPS
ChemSpider  N
ChEMBL  N
Chemical data
Formula C25H34N4O2
Molecular mass 422.56 g/mol
 N   

WAY-100,635 is a piperazine drug and research chemical widely used in scientific studies. It was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor.[1][2][3] It is sometimes referred to as a silent antagonist at the former receptor.[4] It is closely related to WAY-100,135.

In light of its only recently discovered dopaminergic activity, conclusions drawn from studies that employed WAY-100635 as a selective 5-HT1A antagonist may need to be re-evaluated.

Contents

  • Human PET studies 1
    • Radioligands 1.1
  • Other actions 2
  • See also 3
  • External links 4
  • References 5

Human PET studies

In human PET studies WAY-100,635 shows high binding in the cerebral cortex, hippocampus, raphe nucleus and amygdaloid nucleus, while lower in thalamus and basal ganglia.[5] One study described a single case with relatively high binding in the cerebellum.[6]

In relating its binding to subject variables one Swedish study found WAY-100,635 binding in [7] WAY-100,635 binding has also been assessed in connection with clinical depression, where there has been disagreement about the presence and direction of the 5-HT1A receptor binding.[8] In healthy subjects WAY-100,635 binding has been found to decline with age,[9] — though not all studies have found this relationship.[10][11]

Human WAY-100635 binding neuroimaging studies (patients compared to healthy control subjects).
What Result Subjects Ref.
Age Global decrease and particularly in parietal cortex and dorsolateral prefrontal cortex 19 [9]
Age No correlation found 61 [10]
Age No correlation detected 25 [11]
Sex Higher binding in females 25 [11]
TCI self-transcendence and spiritual acceptance personality traits Positive correlation in raphe region 15 males [7]
Lifetime aggression Negative correlation 25 [11]
MADAM binding potential (serotonin transporter binding) Positive correlation in the raphe nuclei and hippocampus 12 males [12]
Genetic variation Result Subjects Ref.
HTR1A.(-1018)C>G polymorphism No difference found 35 [13]
SERT.5-HTTLPR polymorphism Lower binding in "all brain regions" for SS or SL genotypes compared to LL 35 [13]
Disease Result Subjects Ref.
Depressive (with primary, recurrent, familial mood disorders) Reduction in raphe nucleus and mesiotemporal cortex 12+8 [14]
Major depressive disorder (medicated and unmedicated) Reduction in "many of the regions examined" 25+18 [15]
Panic disorder in treated and untreated patients Reducing in binding in raphe in both treated and untreated. Reduced binding in global postsynaptic regions for untreated, while no or little reduction for treated. 9+7+19 [16]
Alzheimer disease Decrease in right medial temporal cortex 10+10 [17]

Radioligands

Labeled with the radioisotope carbon-11 it is used as a radioligand in positron emission tomography (PET) studies to determine neuroreceptor binding in the brain.[18] WAY-100,635 may be labeled in different ways with carbon-11: As [carbonyl-11C]WAY-100,635 or [O-methyl-11C]WAY-100,635, with [carbonyl-11C]WAY-100635 regarded as "far superior".[19] Labeled with tritium WAY-100,635 may also be used in autoradiography.[20] WAY-100,635 has higher 5-HT1A affinity than 8-OH-DPAT.[21]

Other actions

WAY-100,635 has also been found to increase the analgesic effects of opioid drugs in a dose-dependent manner, in contrast to 5-HT1A agonists such as 8-OH-DPAT which were found to reduce opioid analgesia.[22][23] However, since 5-HT1A agonists were also found to reduce opioid-induced respiratory depression and WAY-100,635 was found to block this effect,[24] it is likely that 5-HT1A antagonists might worsen this side effect of opioids. Paradoxically, chronic administration of the very high efficacy 5-HT1A agonist befiradol results in potent analgesia following an initial period of hyperalgesia, an effect most likely linked to desensitisation and/or downregulation of 5-HT1A receptors (i.e. analogous to a 5-HT1A antagonist-like effect).[25][26][27]

See also

External links

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^ a b
  8. ^
  9. ^ a b
  10. ^ a b
  11. ^ a b c d
  12. ^
  13. ^ a b
  14. ^
  15. ^
  16. ^
  17. ^
  18. ^
  19. ^
  20. ^
  21. ^
  22. ^
  23. ^
  24. ^
  25. ^
  26. ^
  27. ^
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.